Terapet SA
Next-generation imaging technology for nuclear medicine.
Terapet SA is a Swiss CERN spin-off founded in 2019 in Geneva by two CERN physicists, Dr. Christina Vallgren (CEO) and Dr. Marcus Palm (CTO), together with a world-leading radiation oncologist Prof. Raymond Miralbell (CSO). The company develops next-generation nuclear imaging systems for oncology in the fields of radiotherapy and nuclear medicine imaging. Terapet holds a strong IP position with 81 granted patents across six families, four registered trademarks, and positive Freedom-to-Operate status. Its platform technology underpins a growing product portfolio: Qual?scan®, a commercial solution for radiotherapy quality assurance; Nucl?scan®, a clinical-stage total-body PET scanner; and a third confidential pre-clinical product.
Only registered users have access to funding information.
Please log in or register to continue. Registration is free.
10.04.2026
Large grants back four Swiss deep tech startups (startupticker.ch)
02.02.2026
Terapet enters the Japanese market with Ansai Medical (startupticker.ch)
06.05.2024
Innosuisse funded 45 Start-up innovation projects (startupticker.ch)
12.03.2024
European funds to propel Swiss projects (startupticker.ch)
18.12.2023
Twenty-eight startups selected for the Innosuisse Scale up Coaching (startupticker.ch)
Last Tweets
No milestones
No Jobs
Videos
Terapet: a Geneva based CERN MedTech spin-off
Invited panelist at the Innosuisse Stakeholder Event on 22.11.2022
TERAPET: Improving Proton Therapy for Cancer Treatments
Elevator Pitch by our CTO, Marcus Palm. TERAPET was among Top10 at Swiss Innovation Challenge 2019
TOP 100 Swiss Startup Award
The TOP 100 Swiss Startup Ranking features the 100 most promising startups that are not older than five years and are selected by a jury of early-stage investors.
Venture Kick
Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.
Venture Leaders Life Sciences
The venture leaders - the members of the Swiss national startup team- have a clear-cut goal. They envision themselves as global players and want to take the first step to their global expansion. The ten-day business development program is specifically structured to help them achieve this goal.
Terapet SA
Next-generation imaging technology for nuclear medicine.
Website:
www.terapet.ch
Headquarter:
Satigny
Foundation Date:
December 2019
Technology:
- Medtech
Sectors:
- Cancer
- Diagnostics
- Drug development platforms
- Imaging and Radiology
- Medical devices
- Medtech
Support received
